For research use only. Not for therapeutic Use.
Bay 41-4109 racemate（Cat No.:I013753）is a small molecule antiviral compound that targets the capsid assembly of hepatitis B virus (HBV). It disrupts the formation of functional viral capsids, interfering with HBV replication and reducing viral load. As a racemic mixture, it contains two enantiomers with potential synergistic activity. Bay 41-4109 has shown promise in preclinical studies for its efficacy against chronic HBV infections, offering a novel mechanism of action compared to existing therapies. Its development contributes to advancing treatments for hepatitis B and improving patient outcomes.
| Catalog Number | I013753 |
| CAS Number | 298708-79-9 |
| Molecular Formula | C₁₈H₁₃ClF₃N₃O₂ |
| Purity | ≥95% |
| Target | HBV |
| Solubility | DMSO: ≥ 37 mg/mL |
| Storage | -20°C |
| IUPAC Name | methyl 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoropyridin-2-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxylate |
| InChI | InChI=1S/C18H13ClF3N3O2/c1-8-14(18(26)27-2)15(11-4-3-9(20)5-12(11)19)25-17(24-8)16-13(22)6-10(21)7-23-16/h3-7,15H,1-2H3,(H,24,25) |
| InChIKey | FVNJBPMQWSIGJK-UHFFFAOYSA-N |
| SMILES | CC1=C(C(N=C(N1)C2=C(C=C(C=N2)F)F)C3=C(C=C(C=C3)F)Cl)C(=O)OC |
| Reference | [1]. Weber O, et al. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res. 2002 May;54(2):69-78.<br>[2]. Stray SJ, et al. BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly. J Mol Recognit. 2006 Nov-Dec;19(6):542-8.<br>[3]. Wu GY, et al. Inhibition of hepatitis B virus replication by Bay 41-4109 and its association with nucleocapsid disassembly. J Chemother. 2008 Aug;20(4):458-67. |
